• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutCurrent TOCInstructions to authors
Gut. Apr 2001; 48(4): 571–577.
PMCID: PMC1728243

Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs



Gastrointestinal Science Research Unit
Royal London Hospital, London, UK

Measurements of luminal pH in the normal gastrointestinal tract have shown a progressive increase in pH from the duodenum to the terminal ileum, a decrease in the caecum, and then a slow rise along the colon to the rectum. Some data in patients with ulcerative colitis suggest a substantial reduction below normal values in the right colon, while limited results in Crohn's disease have been contradictory. Determinants of luminal pH in the colon include mucosal bicarbonate and lactate production, bacterial fermentation of carbohydrates and mucosal absorption of short chain fatty acids, and possibly intestinal transit. Alterations in these factors, as a result of mucosal disease and changes in diet, are likely to explain abnormal pH measurements in inflammatory bowel disease (IBD). It is conceivable that reduced intracolonic pH in active ulcerative colitis impairs bioavailability of 5-aminosalicylic acid from pH dependent release formulations (Asacol, Salofalk) and those requiring cleavage by bacterial azo reductase (sulphasalazine, olsalazine, balsalazide), but further pharmacokinetic studies are needed to confirm this possibility. Reports that balsalazide and olsalazine may be more efficacious in active and quiescent ulcerative colitis, respectively, than Asacol suggest that low pH may be a more critical factor in patients taking directly pH dependent release than azo bonded preparations. Reduced intracolonic pH also needs to be considered in the development of pH dependent colonic release formulations of budesonide and azathioprine for use in ulcerative and Crohn's colitis. This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies.

Full Text

The Full Text of this article is available as a PDF (157K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999 Jun;46(3):183–196. [PubMed]
  • Watson BW, Meldrum SJ, Riddle HC, Brown RL, Sladen GE. pH profile of gut as measured by radiotelemetry capsule. Br Med J. 1972 Apr 8;2(5805):104–106. [PMC free article] [PubMed]
  • Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974 Dec;15(12):999–1004. [PMC free article] [PubMed]
  • Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988 Aug;29(8):1035–1041. [PMC free article] [PubMed]
  • Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989 Dec;3(6):605–613. [PubMed]
  • Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci. 1993 Nov;38(11):1989–1993. [PubMed]
  • Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci. 1998 Apr;43(4):702–705. [PubMed]
  • Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol. 1997 Jan;92(1):114–118. [PubMed]
  • Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, Ewe K, Ramadori G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1998 Jul;12(7):673–678. [PubMed]
  • Ewe K, Schwartz S, Petersen S, Press AG. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci. 1999 Jul;44(7):1434–1439. [PubMed]
  • Colson RH, Watson BW, Fairclough PD, Walker-Smith JA, Campbell CA, Bellamy D, Hinsull SM. An accurate, long-term, pH-sensitive radio pill for ingestion and implantation. Biotelem Patient Monit. 1981;8(4):213–227. [PubMed]
  • McDougall CJ, Wong R, Scudera P, Lesser M, DeCosse JJ. Colonic mucosal pH in humans. Dig Dis Sci. 1993 Mar;38(3):542–545. [PubMed]
  • McNeil NI, Ling KL, Wager J. Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man. Gut. 1987 Jun;28(6):707–713. [PMC free article] [PubMed]
  • Faegenburg D, Kryle LS, Kashiwabara H, Doctor NM, Pai P. Intestinal obstruction caused by ingestion of a Heidelberg capsule: report of a case. Am J Gastroenterol. 1985 Oct;80(10):787–789. [PubMed]
  • Vernia P, Caprilli R, Latella G, Barbetti F, Magliocca FM, Cittadini M. Fecal lactate and ulcerative colitis. Gastroenterology. 1988 Dec;95(6):1564–1568. [PubMed]
  • Rubinstein R, Howard AV, Wrong OM. In vivo dialysis of faeces as a method of stool analysis. IV. The organic anion component. Clin Sci. 1969 Oct;37(2):549–564. [PubMed]
  • Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980 Oct 4;2(8197):712–715. [PubMed]
  • Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJ. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr. 1979 Oct;32(10):2094–2101. [PubMed]
  • Down PF, Agostini L, Murison J, Wrong OM. The interrelations of faecal ammonia, pH and bicarbonate: evidence of colonic absorption of ammonia by non-ionic diffusion. Clin Sci. 1972 Jul;43(1):101–114. [PubMed]
  • Caprilli R, Frieri G, Latella G, Vernia P, Santoro ML. Faecal excretion of bicarbonate in ulcerative colitis. Digestion. 1986;35(3):136–142. [PubMed]
  • Roediger WE, Lawson MJ, Kwok V, Grant AK, Pannall PR. Colonic bicarbonate output as a test of disease activity in ulcerative colitis. J Clin Pathol. 1984 Jun;37(6):704–707. [PMC free article] [PubMed]
  • Chapman MA, Grahn MF, Boyle MA, Hutton M, Rogers J, Williams NS. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994 Jan;35(1):73–76. [PMC free article] [PubMed]
  • Roediger WE, Heyworth M, Willoughby P, Piris J, Moore A, Truelove SC. Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. J Clin Pathol. 1982 Mar;35(3):323–326. [PMC free article] [PubMed]
  • Allan ES, Winter S, Light AM, Allan A. Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. Gut. 1996 Jun;38(6):886–893. [PMC free article] [PubMed]
  • Finnie IA, Taylor BA, Rhodes JM. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut. 1993 Nov;34(11):1552–1558. [PMC free article] [PubMed]
  • Hove H, Mortensen PB. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. Dig Dis Sci. 1995 Jun;40(6):1372–1380. [PubMed]
  • Hove H, Holtug K, Jeppesen PB, Mortensen PB. Butyrate absorption and lactate secretion in ulcerative colitis. Dis Colon Rectum. 1995 May;38(5):519–525. [PubMed]
  • Rao SS, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987 Nov;93(5):934–940. [PubMed]
  • Ritchie JA, Salem SN. Upper intestinal motility in ulcerative colitis, idiopathic steatorrhoea, and the irritable colon syndrome. Gut. 1965 Aug;6(4):325–337. [PMC free article] [PubMed]
  • Manousos ON, Salem SN. Abnormal motility of the small intestine in ulcerative colitis. Gastroenterologia. 1965;104(4):249–257. [PubMed]
  • Jalan KN, Walker RJ, Prescott RJ, Butterworth ST, Smith AN, Sircus W. Faecal stasis and diverticular disease in ulcerative colitis. Gut. 1970 Aug;11(8):688–696. [PMC free article] [PubMed]
  • Lennard-Jones JE, Langman MJ, Jones FA. Faecal stasis in proctocolitis. Gut. 1962 Dec;3(4):301–305. [PMC free article] [PubMed]
  • Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, Yanni G, Mena I, Snape WJ., Jr Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991 Nov;101(5):1289–1297. [PubMed]
  • Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. [PubMed]
  • Dew MJ, Ryder RE, Evans N, Evans BK, Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983 Aug;16(2):185–187. [PMC free article] [PubMed]
  • Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed]
  • Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987 Feb;28(2):196–200. [PMC free article] [PubMed]
  • Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993 Aug;7(4):369–383. [PubMed]
  • Travis SP, Jewell DP. Salicylates for inflammatory bowel disease. Baillieres Clin Gastroenterol. 1994 Jun;8(2):203–231. [PubMed]
  • Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, Söderberg HN, Paumgartner G. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989 Jul;97(1):38–41. [PubMed]
  • Riley SA, Tavares IA, Bennett A, Mani V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988 Aug;26(2):173–177. [PMC free article] [PubMed]
  • Christensen LA, Fallingborg J, Abildgaard K, Jacobsen BA, Sanchez G, Hansen SH, Bondesen S, Hvidberg EF, Rasmussen SN. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. [PubMed]
  • Rijk MC, van Schaik A, van Tongeren JH. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992 Oct;27(10):863–868. [PubMed]
  • Rijk MC, van Hogezand RA, van Schaik A, van Tongeren JH. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol. 1989 Dec;24(10):1179–1185. [PubMed]
  • Christensen LA, Slot O, Sanchez G, Boserup J, Rasmussen SN, Bondesen S, Hansen SH, Hvidberg EF. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol. 1987 Mar;23(3):365–369. [PMC free article] [PubMed]
  • Christensen LA, Fallingborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, Rasmussen SN. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther. 1994 Jun;8(3):289–294. [PubMed]
  • Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. [PMC free article] [PubMed]
  • Mardini HA, Lindsay DC, Deighton CM, Record CO. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987 Sep;28(9):1084–1089. [PMC free article] [PubMed]
  • Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998 Jan;114(1):15–22. [PubMed]
  • TRUELOVE SC, WATKINSON G, DRAPER G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962 Dec 29;2(5321):1708–1711. [PMC free article] [PubMed]
  • Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. [PubMed]
  • Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 1992 May 23;339(8804):1279–1281. [PubMed]
  • Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther. 1998 Dec;12(12):1207–1216. [PubMed]
  • Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May;104(5):1293–1301. [PubMed]
  • Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998 Aug 6;339(6):370–374. [PubMed]
  • Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994 Dec;19(4):278–282. [PubMed]
  • Cammà C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997 Nov;113(5):1465–1473. [PubMed]
  • Frieri G, Pimpo MT, Andreoli A, Annese V, Comberlato M, Corrao G, Palumbo G, Sturniolo GC, Tonelli F, Caprilli R. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. Aliment Pharmacol Ther. 1999 May;13(5):577–582. [PubMed]
  • Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331(13):842–845. [PubMed]
  • Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 1998 Oct;115(4):835–840. [PubMed]
  • Nolen H, 3rd, Fedorak RN, Friend DR. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci. 1995 Jun;84(6):677–681. [PubMed]
  • Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995 Jul 15;123(2):132–142. [PubMed]
  • Zins BJ, Sandborn WJ, McKinney JA, Mays DC, van Os EC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan;37(1):38–46. [PubMed]

Figures and Tables

An external file that holds a picture, illustration, etc.
Object name is gut-medm.f1.jpg

Articles from Gut are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...